Acute lymphoblastic leukemia (ALL) in adults is currently associated with an overall survival rate of around 40% at 5 years. This is an unsatisfactory result that makes it imperative to dissect further the biology of the disease in order to identify highly specific therapeutic targets to implement selectively the cure rate. The recognition of discrete ALL subsets followed by the application of risk-oriented therapies has been a major achievement over the past 30 years.

中文翻译：

---

年轻和成人 Ph-ALL 的现代疗法

目前，成人急性淋巴细胞白血病 (ALL) 的 5 年总生存率约为 40%。这是一个不令人满意的结果，因此必须进一步剖析疾病的生物学特性，以便确定高度特异性的治疗靶点，以选择性地实现治愈率。在过去 30 年中，对离散 ALL 亚群的识别以及风险导向疗法的应用是一项重大成就。